As Puerto Rico struggles in the wake of Hurricane Maria last week, the pharmaceutical manufacturing industry on the island is effectively shut down.
GlaxoSmithKline has a deal to sell a consumer health products plant in the U.S. to CDMO Avara Pharmaceutical Services.
Fresenius Kabi, which has been spending heavily to broaden its capabilities, has started construction on a $250 million project in Illinois.
Roche has struck a deal to unload a plant in Spain to Recipharm, a move that will save 200 jobs as it sheds unneeded small-molecule facilities.
Zydus Cadila, an Indian injectables maker, said it reached a deal with Russia’s Pharm Aid to manufacture its varicella vaccine for the Russian Federation.
Japanese CDMO Ajinomoto Althea is expanding production at its recently completed high-potency products manufacturing facility in San Diego.
The vacant Novartis manufacturing facility in Suffern, New York, sold for $18 million to a buyer who then resold it to a developer for $30 million.
Catalent has agreed to pay $950 million to buy Cook Pharmica and its extensive biologics manufacturing operation in Bloomington, Indiana.
Pfizer is leaning heavily on Celltrion for biosimilar development and manufacturing, but its South Korean partner has stumbled with an FDA inspection.
Japan's Fujifilm Diosynth Biotechnologies has completed a $9 million expansion project of its cell manufacturing facilities in the U.K.